PC
AMRX icon

PA Capital’s Amneal Pharmaceuticals AMRX Stock Holding History

PA Capital’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$132K Buy
+33,874
New +$145K 0.09% 165

Other funds holding AMRX

FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PA Capital's AMRX Position: Q3 2020 in Review

PA Capital opened a new position in Amneal Pharmaceuticals (AMRX) in Q3 2020: 33,874 shares worth $132K. The stake represents 0.09% of the portfolio and ranks #165 among its holdings.

140 funds tracked by Wall St. Rank hold AMRX as of Q3 2020.

  • PA Capital held 33,874 shares of Amneal Pharmaceuticals worth $132K as of Q3 2020.
  • Amneal Pharmaceuticals was a new PA Capital position in Q3 2020.
  • Amneal Pharmaceuticals made up 0.09% of PA Capital's portfolio in Q3 2020, its #165 holding.
  • 140 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.